Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech, Moderna, and Novavax Stocks Sank This Week

By Keith Speights - Jun 18, 2021 at 5:47AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news for one COVID-19 vaccine maker ended up being bad news for all.

What happened

This week hasn't been a great one for COVID-19 vaccine stocks. Shares of BioNTech (BNTX -2.91%) were down 10.2% for the week, as of the market close on Thursday. Moderna (MRNA -5.06%) stock fell 7.5%, and Novavax (NVAX -5.56%) tumbled 14.2%.

The decline for Novavax might be the most puzzling. On Monday, the company announced overwhelmingly positive results from a late-stage study of its COVID-19 vaccine candidate that was conducted in the U.S. and Mexico.

Novavax's good news explained, at least in part, why shares of BioNTech and Moderna fell. The increasing likelihood that another highly effective COVID-19 vaccine could soon be available could mean that the overall global market opportunity for BioNTech (along with its big partner, Pfizer) and Moderna could be reduced somewhat.

So why did Novavax stock sink the most out of these biotech stocks? It could be that investors followed the old adage to "buy the rumor and sell the news." Shares of Novavax surged nearly 50% in the weeks leading up to the company's announcement of its late-stage results.

Healthcare professional giving a shot to a patient.

Image source: Getty Images.

So what

Over the long run, the pullbacks for these vaccine stocks this week won't matter much at all, and there's no cause for investors to be alarmed. Actually, the declines could present a buying opportunity.

The prospects for BioNTech, Moderna, and Novavax should be strong. Orders for the already-authorized COVID-19 vaccines from Pfizer-BioNTech and Moderna keep coming in. Just this week, for example, the U.S. government agreed to buy another 200 million doses of Moderna's vaccine.

Now what

Novavax has another major catalyst on the way soon. The company expects to file for authorizations in the U.S., U.K., and Europe in the third quarter.

Probably the most important thing to watch for BioNTech and Moderna is how their vaccines hold up against the emerging coronavirus variants. That's especially the case for the Delta variant first discovered in India, which has proven to be more contagious and severe than other variants.

Another critical question that remains to be answered is the duration of protection for the leading COVID-19 vaccines. For BioNTech and Moderna, preliminary answers should be on the way in the fall when the first participants in their clinical trials hit their 12-month post-vaccination marks. 

Some experts think that booster doses will be needed within 12 months. If so, the companies should be able to count on recurring revenue from their COVID-19 vaccines on an annual basis. 

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$37.18 (-5.56%) $-2.19
Pfizer Inc. Stock Quote
Pfizer Inc.
$48.58 (-1.40%) $0.69
Moderna, Inc. Stock Quote
Moderna, Inc.
$150.00 (-5.06%) $-8.00
BioNTech SE Stock Quote
BioNTech SE
$147.61 (-2.91%) $-4.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.